Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption
Lila Johnson is a seasoned business reporter with a background in finance, having graduated from the University of North Dakota. She has previously worked with local business journals and focuses on small business success stories and entrepreneurial initiatives.
More from Lila →
Oct 29(Reuters) British consumer health company Haleon cut its annual organic revenue growth forecast on Thursday after weak demand for cold medicines and a regulatory setback in China weighed on sales. • The maker of Advil painkillers and Sensodyne toothpaste now expects full-year organic revenue growth of around 2.5%, down sharply from its prior forecast of 3% to 5% • Analysts had forecast organic revenue growth of 3.2% for 2026, according to a company-compiled poll • Organic revenue for the three months ended September 30 rose 2.6%, also missing market estimates of 3.2% as weaker cough, cold and flu consumption hit orders in North America, its largest market • Sales in China were hurt by a change in raw material classifications that affected imports of over-the-counter Centrum multivitamins, forcing Haleon to suspend shipments of the products • Haleon flagged a £15 million to £20 million hit to its fourth-quarter net revenue from plans to accelerate a new go-to-market